Schneider Nina, Steinberg Ricky, Ben-David Amit, Valensi Johanna, David-Kadoch Galit, Rosenwasser Zohar, Banin Eyal, Levanon Erez Y, Sharon Dror, Ben-Aroya Shay
Division of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
The Nano Center, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Building 206, Room B-840, Ramat Gan 52900, Israel.
Mol Ther Nucleic Acids. 2024 Jan 30;35(1):102130. doi: 10.1016/j.omtn.2024.102130. eCollection 2024 Mar 12.
Adenosine deaminases acting on RNA (ADARs) are endogenous enzymes catalyzing the deamination of adenosines to inosines, which are then read as guanosines during translation. This ability to recode makes ADAR an attractive therapeutic tool to edit genetic mutations and reprogram genetic information at the mRNA level. Using the endogenous ADARs and guiding them to a selected target has promising therapeutic potential. Indeed, different studies have reported several site-directed RNA-editing approaches for making targeted base changes in RNA molecules. The basic strategy has been to use guide RNAs (gRNAs) that hybridize and form a double-stranded RNA (dsRNA) structure with the desired RNA target because of ADAR activity in regions of dsRNA formation. Here we report on a novel pipeline for identifying disease-causing variants as candidates for RNA editing, using a yeast-based screening system to select efficient gRNAs for editing of nonsense mutations, and test them in a human cell line reporter system. We have used this pipeline to modify the sequence of transcripts carrying nonsense mutations that cause inherited retinal diseases in the , , , and genes. Our approach can serve as a basis for gene therapy intervention in knockin mouse models and ultimately in human patients.
作用于RNA的腺苷脱氨酶(ADARs)是一种内源性酶,可催化腺苷脱氨生成肌苷,肌苷在翻译过程中会被读作鸟苷。这种重新编码的能力使ADAR成为一种有吸引力的治疗工具,可在mRNA水平上编辑基因突变并重新编程遗传信息。利用内源性ADARs并将它们引导至选定的靶点具有广阔的治疗潜力。事实上,不同的研究已经报道了几种在RNA分子中进行靶向碱基改变的位点定向RNA编辑方法。基本策略是使用引导RNA(gRNA),由于在双链RNA(dsRNA)形成区域存在ADAR活性,gRNA会与所需的RNA靶点杂交并形成双链RNA结构。在此,我们报告了一种新的流程,用于鉴定作为RNA编辑候选对象的致病变体,该流程使用基于酵母的筛选系统来选择用于编辑无义突变的高效gRNA,并在人细胞系报告系统中对其进行测试。我们已使用该流程来修改携带导致视网膜遗传性疾病的无义突变的 、 、 和 基因转录本的序列。我们的方法可作为在敲入小鼠模型乃至最终在人类患者中进行基因治疗干预的基础。